Clinical Trials on ASA 1-2 Requiring Intravenous Cannulation for General Anaesthesia
Total 137 results
-
Institute of Child HealthCompletedASA 1-2 Requiring Intravenous Cannulation for General AnaesthesiaUnited Kingdom
-
Institute of Child HealthCompletedAsa 1 and 2 Patients for Elective Surgery Requiring Caudal as Part of Their CareUnited Kingdom
-
Jawaharlal Institute of Postgraduate Medical Education...CompletedOrotracheal Intubation in Infants Requiring General Anaesthesia for SurgeryIndia
-
University of California, IrvineWithdrawnAnesthetized Healthy Patients (ASA 1 or 2) in the Supine Position, Excluding Head, Neck and Head Surgeries | Anesthetized Patient With Severe Systemic Disease (ASA 3 or 4)United States
-
University Hospital, GhentTerminatedASA Class I/II Patients Scheduled for Surgery Under General AnesthesiaBelgium
-
Allina Health SystemCompletedPain | Local Anesthesia for Peripheral Intravenous CatheterizationUnited States
-
University College London HospitalsUniversity College, London; Department of Health, United KingdomCompletedDiabetes (Insulin-requiring, Type 1 or Type 2)United Kingdom
-
University of VirginiaDexCom, Inc.; Tandem Diabetes Care, Inc.WithdrawnType 1 Diabetes | End Stage Renal Disease (ESRD) | Insulin-requiring Type 2 Diabetes Mellitus
-
Merz Pharmaceuticals GmbHLLC Merz Pharma, RussiaCompletedFemale Pattern Hair Loss | Androgenetic Alopecia (AGA) | Ludwig Type 1 | Ludwig Type 2Russian Federation
-
National Institute of Diabetes and Digestive and...CompletedProtocol #1:Behavioral Therapy + Placebo or Sibutramine | Protocol #2: Behavioral Therapy + Meal Replacement or Conventional Food
-
University of SaskatchewanGovernment of Canada; Vaccine Formulation Institute (VFI); Government of Saskatchewan and other collaboratorsCompletedDouble Vaccinated for COVID-19 (For Phase 1 of the Study) | Acute Respiratory Syndrome Coronavirus 2 (For Phase 2 Exploratory Group)Canada
-
National Institute of Neurological Disorders and...TerminatedMyotonic Dystrophy Type-1 | Myotonic Dystrophy Type-2United States
-
Mannkind CorporationCompletedDiabetes, Type 2 | Diabetes, Type 1United States, Spain, Canada, Russian Federation, Czech Republic, Poland, Ukraine, United Kingdom
-
Centre Hospitalier Universitaire DijonTerminatedPatients With Type 1 or Type 2 Diabetes | Patients With a Type A or B Behaviour ProfileFrance
-
University of California, Los AngelesActive, not recruitingSpinocerebellar Ataxias | Spinocerebellar Ataxia 3 | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6 | MSA-CUnited States
-
Nantes University HospitalUnknownLong QT Syndrome Type 1 or 2France
-
Benha UniversityRecruitingEmergence Delirium | Sevoflurane | Intravenous AnesthesiaEgypt
-
Baylor College of MedicineChildren's Hospital of Philadelphia; Children's Hospital Colorado; Seattle Children... and other collaboratorsRecruitingOrnithine Transcarbamylase Deficiency | Urea Cycle Disorder | Argininosuccinic Aciduria | Hyperargininemia | Citrullinemia 1 | ARGI Deficiency | ASL Deficiency | ASS DeficiencyUnited States
-
Lupin Ltd.WithdrawnMyotonic Dystrophy Type 1 and Type 2
-
Centre Hospitalier Universitaire DijonCompletedDiabetes Type 1 or 2 With Diabetic RetinopathyFrance
-
BIOTRONIK IsraelCompletedMyocardial Ischemia | Coronary Artery Disease | Diabetes Mellitus Type 1 or 2Israel
-
BIOTRONIK Asia Pacific Pte LtdCompletedMyocardial Ischemia | Coronary Artery Disease | Diabetes Mellitus Type 1 or 2China, India, Malaysia, Vietnam, Sri Lanka
-
Poznan University of Medical SciencesCompletedMetabolic Syndrome | Diabetes Mellitus Type 2 | Hyperlipidemia | Renal Failure Chronic Requiring HemodialysisPoland
-
Zhujiang HospitalNot yet recruitingEfficacy Endpoint: no New Cerebrovascular Adverse Events Within 1 Year | Safety Endpoint: no New Moderate or Serious Adverse Events Within 1 Year | All-cause Mortality Events (Within 1 Year) | Incident Ischemic Stroke Events (Within 1 Year) | New Hemorrhagic Stroke Events (Within 1 Year) | New... and other conditions
-
University of FloridaAcorda TherapeuticsCompletedSpinocerebellar Ataxias Type 1 | Spinocerebellar Ataxias Type 2 | Spinocerebellar Ataxias Type 3 | Spinocerebellar Ataxias Type 6United States
-
Baylor College of MedicineChildren's National Research InstituteRecruitingOrnithine Transcarbamylase Deficiency | Urea Cycle Disorder | Carbamyl Phosphate Synthetase Deficiency | Argininosuccinic Aciduria | Hyperargininemia | Citrullinemia 1 | ARGI Deficiency | ASL Deficiency | ASS Deficiency | NAGS DeficiencyUnited States
-
University Hospital Center of MartiniqueClinique Antilles-Guyane; Fondation de FranceCompleted1- Women | 2- HIV Infection | 3- Followed in West Indies and French Guiana for His Infection | 4- Acceptance of the Use of Nadis® Medical FilesMartinique
-
Herlev and Gentofte HospitalCompletedSudden Cardiac Death | Long Qt Syndrome 1-2Denmark
-
Myotonic Dystrophy FoundationRecruitingMyotonic Dystrophy | Myotonic Dystrophy 1 | Steinert's Disease | Congenital Myotonic Dystrophy | PROMM (Proximal Myotonic Myopathy) | Steinert Disease | Dystrophia Myotonica 1 | Myotonic Dystrophy 2 | Dystrophia Myotonica | Dystrophia Myotonica 2 | Myotonia Dystrophica | Myotonic Dystrophy, Congenital | Myotonic... and other conditionsUnited States
-
Allarity TherapeuticsCompletedPhase 1: Advanced or Refractory Solid Tumours | Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin CancerDenmark
-
University Hospital, BonnForschungszentrum Juelich; The Marigold Foundation; Life and Brain Center BonnCompletedMyotonic Dystrophy 1 | Myotonic Dystrophy 2
-
NYU Langone HealthCompletedNeurofibromatosis 1 and 2 (NF1 and NF2)United States
-
Cadent TherapeuticsWithdrawnSpinocerebellar Ataxia Type 3 | Spinocerebellar Ataxias | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6 | Spinocerebellar Ataxia Type 10 | Spinocerebellar Ataxia Type 7 | Spinocerebellar Ataxia Type 8 | Spinocerebellar Ataxia Type 17 | ARCA1 - Autosomal Recessive...United States
-
Avidity Biosciences, Inc.RecruitingPhase 1/2 Study of AOC 1020 in Adults With Facioscapulohumeral Muscular Dystrophy (FSHD) (FORTITUDE)Muscular Dystrophies | Muscular Dystrophy, Facioscapulohumeral | FSHD | Facio-Scapulo-Humeral Dystrophy | FMD | Facioscapulohumeral Muscular Dystrophy 1 | FSHD2 | FSHD1 | FMD2 | Fascioscapulohumeral Muscular Dystrophy | Fascioscapulohumeral Muscular Dystrophy Type 1 | Fascioscapulohumeral Muscular Dystrophy... and other conditionsUnited States, United Kingdom, Canada
-
University Of PerugiaUnknownThe Primary Study Objective is to Assess the Efficacy and | Safety of Extended 4-week Heparin Prophylaxis Compared to | Prophylaxis Given for 8±2 Days After Planned Laparoscopic | Surgery for Colorectal Cancer. | The Clinical Benefit Will be Evaluated as the Difference in | the Incidence of... and other conditionsItaly
-
University of FloridaUniversity of California, Los Angeles; National Ataxia FoundationRecruitingSpinocerebellar Ataxia Type 3 | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6United States
-
Sclnow Biotechnology Co., Ltd.Not yet recruitingSpinocerebellar Ataxia Type 3 | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6
-
AIO-Studien-gGmbHNovartis Pharmaceuticals; Assign Data Management and Biostatistics GmbHCompletedNeuroendocrine Carcinoma, Grade 3 | Poorly Differentiated Malignant Neuroendocrine Carcinoma | Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 | Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma]... and other conditionsGermany
-
Assistance Publique - Hôpitaux de ParisCompletedSpinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia, Autosomal Recessive 3 | Episodic Ataxia, Type 7France
-
Teachers College, Columbia UniversityActive, not recruitingSpinocerebellar Ataxia Type 3 | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6 | Spinocerebellar Ataxia Type 7United States
-
Passage Bio, Inc.Active, not recruitingGM1 Gangliosidosis | GM1 Gangliosidosis, Type I | GM1 Gangliosidosis, Type 2 | Beta-Galactosidase-1 (GLB1) DeficiencyUnited States, Canada, United Kingdom, Turkey, Brazil
-
University of RochesterNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingMuscular Dystrophy | Myotonic Dystrophy Type 2 | Myotonic Dystrophy Type 1 | Myotonic Dystrophy | Facioscapulohumeral Muscular Dystrophy | Steinert's Disease | Congenital Myotonic Dystrophy | PROMM (Proximal Myotonic Myopathy) | Myotonic Muscular DystrophyUnited States
-
University of ChicagoPfizer; Biogen; APDM Wearable TechnologiesActive, not recruitingSpinocerebellar Ataxia Type 3 | Friedreich Ataxia | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6United States
-
Biohaven Pharmaceuticals, Inc.Active, not recruitingSpinocerebellar Ataxia Type 3 | Spinocerebellar Ataxias | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6 | Spinocerebellar Ataxia Type 10 | Spinocerebellar Ataxia Type 7 | Spinocerebellar Ataxia Type 8United States, China
-
Johns Hopkins UniversityJuvenile Diabetes Research Foundation; National Eye Institute (NEI)RecruitingType 1 Diabetes | Type 2 Diabetes | Cystic Fibrosis-related DiabetesUnited States
-
NYU Langone HealthNovartis Pharmaceuticals; The Children's Tumor FoundationCompletedNeurofibromatosis Type IIUnited States
-
Manchester University NHS Foundation TrustCompletedNeurofibromatosis Type 2United Kingdom
-
PTC TherapeuticsUnited States Department of DefenseTerminated
-
Recursion Pharmaceuticals Inc.RecruitingNeurofibromatosis Type 2United States
-
Massachusetts Eye and Ear InfirmaryRecruiting